Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SRx Health Solutions (SRXH) Operating Leases (2019 - 2025)

SRx Health Solutions' Operating Leases history spans 7 years, with the latest figure at $3.9 million for Q2 2025.

  • For Q2 2025, Operating Leases rose 10316.22% year-over-year to $3.9 million; the TTM value through Jun 2025 reached $3.9 million, up 10316.22%, while the annual FY2024 figure was $5000.0, 92.54% down from the prior year.
  • Operating Leases reached $3.9 million in Q2 2025 per SRXH's latest filing, up from $5000.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $5.6 million in Q3 2024 to a low of $5000.0 in Q4 2021.
  • Average Operating Leases over 5 years is $649375.0, with a median of $74500.0 recorded in 2023.
  • Peak YoY movement for Operating Leases: plummeted 97.45% in 2021, then skyrocketed 10316.22% in 2025.
  • A 5-year view of Operating Leases shows it stood at $5000.0 in 2021, then surged by 2380.0% to $124000.0 in 2022, then crashed by 45.97% to $67000.0 in 2023, then crashed by 92.54% to $5000.0 in 2024, then skyrocketed by 76980.0% to $3.9 million in 2025.
  • Per Business Quant, the three most recent readings for SRXH's Operating Leases are $3.9 million (Q2 2025), $5000.0 (Q1 2025), and $5000.0 (Q4 2024).